GSTM4: A Promising Drug Target and Biomarker (G2948)

Target Name: GSTM4

NCBI ID: G2948

GSTM4

GSTM4: A Promising Drug Target and Biomarker

GSTM4 (GTM4) is a promising drug target and biomarker for various diseases, including cancer. It is a member of the G-protein-coupled receptor (GPCR) family, which is a large family of transmembrane proteins that play a crucial role in cellular signaling. GSTM4 is a non-c coding RNA (ncRNA), which means it is not a protein but instead a RNA molecule that has important functions in the cell.

GSTM4 is a key regulator of cell signaling, particularly in the context of the immune system. It is involved in the development and maintenance of T-cell responses, which are critical for fighting off infections and cancer. GSTM4 is also involved in the regulation of cell adhesion, which is important for the formation of tissues and organs during development.

In addition to its role in cell signaling, GSTM4 is also a potential biomarker for various diseases. For example, it has been shown to be downregulated in various types of cancer, including breast, ovarian, and prostate cancer. This suggests that GSTM4 may be a useful target for cancer therapies that aim to increase the activity of T-cells and enhance their ability to fight off cancer cells.

GSTM4 is also a potential drug target for other diseases, including cardiovascular disease and neurodegenerative disorders. For example, GSTM4 has been shown to be involved in the regulation of blood pressure and has been linked to the development of hypertension. Additionally, GSTM4 has been linked to the development of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease.

GSTM4 is a small molecule that can be easily synthesized and has been shown to be safe in both humans and animals. It is a potential drug candidate for various diseases and could be a valuable addition to our arsenal of treatments. As more research is conducted on GSTM4, it is likely that its potential therapeutic uses will continue to grow.

In conclusion, GSTM4 is a promising drug target and biomarker for various diseases. Its role in cell signaling and its potential as a drug target make it an attractive candidate for further research and development. As more research is conducted on GSTM4, its potential therapeutic uses will continue to grow and it may become a valuable addition to our treatments for various diseases.

Protein Name: Glutathione S-transferase Mu 4

Functions: Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles (PubMed:8203914, PubMed:8373352). Catalyzes the conjugation of leukotriene A4 with reduced glutathione (GSH) to form leukotriene C4 (PubMed:27791009). Can also catalyzes the transfer of a glutathionyl group from glutathione (GSH) to 13(S),14(S)-epoxy-docosahexaenoic acid to form maresin conjugate in tissue regeneration 1 (MCTR1), a bioactive lipid mediator that possess potent anti-inflammatory and proresolving actions (PubMed:27791009)

The "GSTM4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GSTM4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets